British-Swedish company AstraZeneca on Sunday said that a safety review of people inoculated with its coronavirus vaccine has shown no evi...
British-Swedish company AstraZeneca on Sunday said that a safety review of people inoculated with its coronavirus vaccine has shown no evidence of increased risk of blood clots, even as two more European countries halted vaccinations.
The Cambridge-based company said it has reviewed data from 17 million people vaccinated in the United Kingdom and European Union after reports of blood clotting problems among people who recently received shots in Norway.
“A careful review of all available safety data of more than 17 million people vaccinated in the European Union and UK with Covid-19 vaccine AstraZeneca has shown no evidence of an increased risk of pulmonary embolism, deep vein thrombosis or thrombocytopenia, in any defined age group, gender, batch or in any particular country,” the company said in a statement.
As of March 8, AstraZeneca said there had been 15 cases of deep vein thrombosis and 22 of pulmonary embolism reported among those who took the jab. “This is much lower than would be expected to occur naturally in a general population of this size and is similar across other licensed Covid-19 vaccines,” it added.
The Netherlands and Ireland on Sunday became the latest countries to suspend the use of the AstraZeneca vaccine as concerns mount about its possible side effects. Other countries...
